Toremifene is one of the newer SERMs to come to market in the past ten years. Toremifene has been shown to increase LH, SHBG and testosterone in men in a similar manner to tamoxifen1,2. This SERM is also in clinical trials to prevent the progression of prostate cancer3. Many of the things that were said about tamoxifen would apply to toremifene as they seem to perform in very similar manners. Toremifene seems to perform better than tamoxifen with regard to elevation of HDL and reduction of triglycerides4. There have not been any studies done with toremifene with regard to gynecomastia as yet. Because this is a newer drug that is still under patent, it tends to be much more expensive than generic tamoxifen.
1. Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril. Aug 8, 2008
2. Farmakiotis D, Farmakis C, Rousso D, Kourtis A, Katsikis I, Panidis D. The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia. Fertil Steril. 88(4):847-53, 2007
3. Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene–a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 15(3):293-305. Review, 2006
4. Kusama M, Miyauchi K, Aoyama H, Sano M, Kimura M, Mitsuyama S, Komaki K, Doihara H. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat. 88(1):1-8, 2004